Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement

Robert P. Baughman, Marjolein Drent, Mani S. Kavuru et al. · American Journal of Respiratory and Critical Care Medicine · 2006 · 709 citations

Medicine, Immunology, Pharmacotherapy +12

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Won Park, Paweł Hrycaj, Volodymyr Kovalenko et al. · Annals of the Rheumatic Diseases · 2013 · 604 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Definition and Consensus Diagnostic Criteria for Neurosarcoidosis

Barney J. Stern, Walter Royal, Jeffrey M. Gelfand et al. · JAMA Neurology · 2018 · 381 citations

Medicine, Clinical Sciences, Neurology +10

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

Jonathan Kay, Monika Schoels, Thomas Dörner et al. · Annals of the Rheumatic Diseases · 2017 · 216 citations

Medicine, Dermatology, Pharmacotherapy +17